Connect Biopharma Holdings Ltd (NASDAQ:CNTB) — Market Cap & Net Worth
Market Cap & Net Worth: Connect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Ltd (NASDAQ:CNTB) has a market capitalization of $138.08 Million ($138.08 Million) as of May 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17947 globally and #4003 in its home market, demonstrating a -1.98% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Connect Biopharma Holdings Ltd's stock price $2.47 by its total outstanding shares 55903513 (55.90 Million). Analyse CNTB cash generation efficiency to see how efficiently the company converts income to cash.
Connect Biopharma Holdings Ltd Market Cap History: 2021 to 2026
Connect Biopharma Holdings Ltd's market capitalization history from 2021 to 2026. Data shows change from $287.90 Million to $138.08 Million (-32.51% CAGR).
Index Memberships
Connect Biopharma Holdings Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #497 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1750 of 3165 |
Weight: Connect Biopharma Holdings Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Connect Biopharma Holdings Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Connect Biopharma Holdings Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.96x
Connect Biopharma Holdings Ltd's market cap is 2.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $77.15 Million | $26.03 Million | -$15.63 Million | 2.96x | N/A |
Competitor Companies of CNTB by Market Capitalization
Companies near Connect Biopharma Holdings Ltd in the global market cap rankings as of May 5, 2026.
Key companies related to Connect Biopharma Holdings Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Connect Biopharma Holdings Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Connect Biopharma Holdings Ltd's market cap moved from $287.90 Million to $ 138.08 Million, with a yearly change of -32.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $138.08 Million | -12.41% |
| 2025 | $157.65 Million | +104.35% |
| 2024 | $77.15 Million | +16.95% |
| 2023 | $65.97 Million | +35.98% |
| 2022 | $48.51 Million | -83.15% |
| 2021 | $287.90 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Connect Biopharma Holdings Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $138.08 Million USD |
| MoneyControl | $138.08 Million USD |
| MarketWatch | $138.08 Million USD |
| marketcap.company | $138.08 Million USD |
| Reuters | $138.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as a… Read more